Ironshore Pharmaceuticals and Development

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Ironshore Pharmaceuticals and Development sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials none currently recruiting 5 completed later-stage tilt upper quartile by trial count

Ironshore Pharmaceuticals and Development: 6 sponsored US clinical trials, none currently recruiting.

Ironshore Pharmaceuticals and Development sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 4 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Attention Deficit Hyperactivity Disorder, with 1 trials.

Upper-quartile sponsor footprint

Ironshore Pharmaceuticals and Development sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

6 total, page 1 of 1

TERMINATED Phase 3

Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD

NCT06431256
COMPLETED Phase 2

A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD

NCT02884544
COMPLETED Phase 3

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting

NCT02520388
COMPLETED Phase 3

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting

NCT02493777
COMPLETED Phase 3

A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD

NCT02255513
COMPLETED Phase 1

Pharmacokinetics of HLD200 in Children and Adolescents With ADHD

NCT01907360

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1
Phase 3 4

Therapeutic Areas

Attention Deficit Hyperactivity Disorder 1

How the Ironshore Pharmaceuticals and Development archive is shaped

6 indexed studies, none listed as recruiting (0% open); 5 completed (83%).

Phase mix: 4 late (III/IV) vs 2 early (I/II) (later-stage heavy).

Top condition: Attention Deficit Hyperactivity Disorder (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Ironshore Pharmaceuticals and Development: archived-pipeline peers nationwide

Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Ironshore Pharmaceuticals and Development sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60%80% Total trials Recruiting share Ironshore Pharmaceuticals and Development23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan Branch10xBio22nd Century Group3-C Institute for Social Development3 Waves Wellness
Ironshore Pharmaceuticals and Development sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Ironshore Pharmaceuticals and Development sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Ironshore Pharmaceuticals and Development page

6 registered trials is a research-attention snapshot, not an endorsement of Ironshore Pharmaceuticals and Development or any single study.

  • None of Ironshore Pharmaceuticals and Development's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Attention Deficit Hyperactivity Disorder is the condition Ironshore Pharmaceuticals and Development studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Attention Deficit Hyperactivity Disorder trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Ironshore Pharmaceuticals and Development pipeline card: 6 registered trials from official public datasets.Report a data error.